Anti-Blys monoclonal antibody and pharmaceutical composition containing anti-Blys monoclonal antibody

The invention relates to the technical field of gene engineering antibodies and especially relates to a gene engineering antibody specifically binding with a B lymphocyte stimulator (Blys), a pharmaceutical composition containing the gene engineering antibody and a kit containing the gene engineering antibody. A heavy chain variable region of the gene engineering antibody contains amino acid sequences shown in the formulas of SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, or a light chain variable region of the gene engineering antibody contains amino acid sequences shown in the formulas of SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The invention also provides the anti-Blys monoclonal antibody. The anti-Blys monoclonal antibody is produced by a cell strain having the preservation number of CGMCC No.7352. The anti-Blys monoclonal antibody has strong binding affinity to Blys, can inhibit Blys and IM9 cell surface receptors, can inhibit Blys-induced mouse spleen cell proliferation and can be used for treating Blys-related diseases. The anti-Blys monoclonal antibody has good antibody activity and good singularity, can be prepared easily and has wide clinical application and experiment application prospects.